EP1207906A4 - Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies - Google Patents

Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies

Info

Publication number
EP1207906A4
EP1207906A4 EP00965561A EP00965561A EP1207906A4 EP 1207906 A4 EP1207906 A4 EP 1207906A4 EP 00965561 A EP00965561 A EP 00965561A EP 00965561 A EP00965561 A EP 00965561A EP 1207906 A4 EP1207906 A4 EP 1207906A4
Authority
EP
European Patent Office
Prior art keywords
antibodies
patients
treatment
bone marrow
hodgkins lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00965561A
Other languages
German (de)
French (fr)
Other versions
EP1207906A1 (en
Inventor
William H Rastetter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of EP1207906A1 publication Critical patent/EP1207906A1/en
Publication of EP1207906A4 publication Critical patent/EP1207906A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00965561A 1999-08-11 2000-07-25 Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies Withdrawn EP1207906A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14828799P 1999-08-11 1999-08-11
US148287P 1999-08-11
PCT/US2000/040459 WO2001010462A1 (en) 1999-08-11 2000-07-25 Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies

Publications (2)

Publication Number Publication Date
EP1207906A1 EP1207906A1 (en) 2002-05-29
EP1207906A4 true EP1207906A4 (en) 2005-07-06

Family

ID=22525101

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00965561A Withdrawn EP1207906A4 (en) 1999-08-11 2000-07-25 Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies

Country Status (10)

Country Link
EP (1) EP1207906A4 (en)
JP (1) JP2003513012A (en)
CN (2) CN100389825C (en)
AU (1) AU784971B2 (en)
CA (1) CA2378646A1 (en)
MX (1) MXPA02001398A (en)
MY (1) MY136635A (en)
NO (1) NO20020639L (en)
TW (1) TWI279233B (en)
WO (1) WO2001010462A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020027311A (en) 1999-05-07 2002-04-13 제넨테크, 인크. Treatment of Autoimmune Diseases with Antagonists Which Bind to B Cell Surface Markers
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
KR100932340B1 (en) 2002-10-17 2009-12-16 젠맵 에이/에스 Human monoclonal antibodies against CD20
CN103833854B (en) 2002-12-16 2017-12-12 健泰科生物技术公司 Immunoglobulin variants and application thereof
EP1613350B1 (en) 2003-04-09 2009-03-18 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
KR101412271B1 (en) 2003-05-09 2014-06-25 듀크 유니버시티 CD20-Specific Antibodies and Methods of Employing Same
PT1631313E (en) 2003-06-05 2015-07-02 Genentech Inc Combination therapy for b cell disorders
BRPI0416262B1 (en) 2003-11-05 2022-04-12 Roche Glycart Ag Humanized type II anti-human cd20 antibody, its production method, its uses, as well as isolated polynucleotide, expression vector and pharmaceutical composition
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
TW201422238A (en) 2004-06-04 2014-06-16 Genentech Inc Use of CD20 antibody in treatment of multiple sclerosis and an article for the use
CN101001873B (en) 2004-08-04 2013-03-13 曼璀克生物科技有限责任公司 Variant fc regions
US7601335B2 (en) 2005-05-20 2009-10-13 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
WO2007014238A2 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. Single dose use of cd20-specific binding molecules
SI1912675T1 (en) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc B-cell reduction using cd37-specific and cd20-specific binding molecules
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
PL4365189T3 (en) 2007-07-09 2025-05-26 F. Hoffmann-La Roche Ag Prevention of disulfide bond reduction during recombinant production of polypeptides
EP2233149B1 (en) 2007-10-16 2016-02-10 ZymoGenetics, Inc. Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for treatment of autoimmune disease
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
SG189772A1 (en) 2008-04-11 2013-05-31 Trubion Pharmaceuticals Inc Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
JP5738196B2 (en) * 2008-12-22 2015-06-17 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Combination of Aurora kinase inhibitor and anti-CD20 antibody
JO3434B1 (en) 2009-07-31 2019-10-20 Millennium Pharm Inc Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
HRP20200768T4 (en) 2009-08-11 2025-03-28 F. Hoffmann - La Roche Ag PRODUCTION OF PROTEIN IN CELL GROWTH MEDIA WITHOUT GLUTAMINE
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
RU2012140021A (en) 2010-02-19 2014-03-27 Миллениум Фармасьютикалз, Инк. CRYSTAL FORMS 4 - {[9-CHLOR-7- (2-FLUOR-6-METHOXYPHENYL) -5H-PYRIMIDO [5,4-d] [2] BENZAZEPIN-2-IL] AMINO} -2-SODIUM METHOZIBENZOATE
WO2012088272A1 (en) * 2010-12-21 2012-06-28 Duke University Methods and compositions combining immunotherapy with monocyte activation
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
JP6360881B2 (en) 2013-03-22 2018-07-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Combination of catalytic MTORC1 / 2 inhibitor and selective inhibitor of Aurora A kinase
EP3247395A1 (en) * 2015-01-23 2017-11-29 Immunomedics, Inc. Combination therapy with anti-cd74 and anti-cd20 antibodies in patients with relapsed and refractory b-cell non-hodgkin's lymphoma
MX2017015493A (en) 2015-05-30 2018-02-09 Molecular Templates Inc De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same.
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Anti-transferrin receptor antibodies with tailored affinity
UA126278C2 (en) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Cd3 binding polypeptides
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
CN114057885A (en) 2015-10-02 2022-02-18 豪夫迈·罗氏有限公司 Bispecific anti-human CD20/human transferrin receptor antibody and methods of use
US20190192703A1 (en) * 2016-09-16 2019-06-27 Nordic Nanovector Asa Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan
CN108421048B (en) * 2016-09-28 2021-04-20 首都医科大学附属北京世纪坛医院 Nano activated carbon targeted drug delivery system, preparation method and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009160A1 (en) * 1998-08-11 2000-02-24 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
WO2001010460A1 (en) * 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Treatment of intermediate- and high-grade non-hodgkins lymphoma with anti-cd20 antibody
EP1207904B1 (en) * 1999-08-11 2008-03-05 Biogen Idec Inc. New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69303494T2 (en) * 1992-11-13 1997-01-16 Idec Pharma Corp THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES AGAINST HUMAN B LYMPHOCYTIC LIMITED DIFFERENTIATION ANTIQUES FOR THE TREATMENT OF B CELL LYMPHOMA
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009160A1 (en) * 1998-08-11 2000-02-24 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
WO2001010460A1 (en) * 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Treatment of intermediate- and high-grade non-hodgkins lymphoma with anti-cd20 antibody
EP1207904B1 (en) * 1999-08-11 2008-03-05 Biogen Idec Inc. New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 20 September 2006 (2006-09-20), LEAHY MICHAEL F. ET AL: "Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.", Database accession no. NLM16940276 *
GREGORY S.A. ET AL: "Relationship of degree of bone marrow involvement with hematologic toxicity in patients with non-Hodgkin's lymphoma treated with tositumomab and iodine I 131 tositumomab", PROC AM SOC CLIN ONC, vol. 22, 2314, Retrieved from the Internet <URL:http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=100932> [retrieved on 20100107] *
JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 20 SEP 2006, vol. 24, no. 27, 20 September 2006 (2006-09-20), pages 4418 - 4425, ISSN: 1527-7755 *
NGUYEN D T ET AL: "IDEC-C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patients", EUROPEAN JOURNAL OF HAEMATOLOGY, vol. 62, no. 2, February 1999 (1999-02-01), pages 76 - 82, XP001056722, ISSN: 0902-4441 *
See also references of WO0110462A1 *
TSAI D E ET AL: "Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation", BONE MARROW TRANSPLANTATION, vol. 24, no. 5, 1 September 1999 (1999-09-01), pages 521 - 526, XP002327600, ISSN: 0268-3369 *
WISEMAN ET AL: 'IDEC-Y2B8 radioimmunotherapy: Baseline bone marrow involvement and platelet count are better predictors of hematologic toxicity than dosimetry' BLOOD. vol. 92, no.10, suppl. 1, part 1-2, 15 November 1998, page 417A, Abstract# 1721 *
WISEMAN G. ET AL: "RADIOIMMUNOTHERAPY: BASELINE BONE MARROW INVOLVEMENT AND PLATELET COUNT ARE BETTER PREDICTORS OF HEMATOLOGIC TOXICITY THAN DOSIMETRY", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 92, no. 10, SUPPL. 01, 15 November 1998 (1998-11-15), pages 417A, XP001056771, ISSN: 0006-4971 *
WITZIG THOMAS E ET AL: "Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma", JOURNAL OF CLINICAL ONCOLOGY, vol. 17, no. 12, December 1999 (1999-12-01), pages 3793 - 3803, XP002327601, ISSN: 0732-183X *

Also Published As

Publication number Publication date
MXPA02001398A (en) 2002-08-12
HK1048945A1 (en) 2003-04-25
AU784971B2 (en) 2006-08-10
NO20020639L (en) 2002-04-11
NO20020639D0 (en) 2002-02-08
MY136635A (en) 2008-11-28
CN101259270A (en) 2008-09-10
TWI279233B (en) 2007-04-21
AU7626000A (en) 2001-03-05
WO2001010462A1 (en) 2001-02-15
CN1373671A (en) 2002-10-09
EP1207906A1 (en) 2002-05-29
CA2378646A1 (en) 2001-02-15
CN100389825C (en) 2008-05-28
JP2003513012A (en) 2003-04-08

Similar Documents

Publication Publication Date Title
EP1207906A4 (en) Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
EP1227836A4 (en) Treatment of intermediate- and high-grade non-hodgkins lymphoma with anti-cd20 antibody
AUPQ893200A0 (en) Medical residue treatment
IL133571A0 (en) Medical instrument for treating biological tissue
GB2353220B (en) Surgical instrument
PT1066838E (en) Bone tissue regenerating composition
AU6869598A (en) Titanium molybdenum hafnium alloys for medical implants and devices
AU138426S (en) An electrode for medical use
IL144981A0 (en) Treatment of autoimmune disease
AU7434101A (en) Treatment of bone diseases
PT1716853E (en) Treatment of cancers of the human body using et743
PL340948A1 (en) Syringe, in particular that for taking blood samples from patients
IL148051A0 (en) Finger-guided surgical instrument
PL358848A1 (en) Bone treatment material
EP1173470A4 (en) Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
AU3177500A (en) Proteins for diagnosis and treatment of breast cancer
GB9904252D0 (en) Composition for the treatment of pain
GB2341099B (en) Clinical table for treatment of the spine
GB0130539D0 (en) Bone marrow-specific protein
AUPQ421299A0 (en) Treatment of bone disorder
AU2001253219A1 (en) Composition for treatment of autoimmune disease
GB2341314B (en) Medical patient suspension apparatus
AU140446S (en) Tissue processing instrument
GB9900136D0 (en) Multi-functional medical patients suspension apparatus
IL145242A0 (en) Treatment of hiatial hernia

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020308

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOGEN IDEC INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20050523

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOGEN IDEC INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100729

18W Application withdrawn

Effective date: 20100729